New Treatment Option for ADHD: Unique Pharmacokinetic Profile and Range of Dosing Options
The US Food and Drug Administration has approved Tris Pharma’s Dyanavel XR (amphetamine), extended release once-daily tablets for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and older...Dyanavel XR is a central nervous system stimulant prescription medicine used for the treatment of ADHD in individuals aged 6 years and older.
Other Articles in this Edition
From Day 1: ADHD and Comorbid Conditions
New Treatment Option for ADHD: Unique Pharmacokinetic Profile and Range of Dosing Options
Micronutrient Supplementation Linked to Positive Global Effects in Pediatric ADHD
Communication Strategies for Management of Pediatric ADHD: Do Care Managers Improve Outcomes?
Why is ADHD awareness important?
How to get organized at home when you have ADHD or mental health issues